menu
    • menu
    [{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melatonin? Stem Cells? Researchers Step Up With Unconventional Approaches To COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Melatonin","moa":"Melatonin receptor type 1A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland .."},{"orgOrder":0,"company":"Kinderfarms","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinderfarms Announces the Launch of Kinderlyte\u00ae Sleep and Immunity","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Melatonin","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Kinderfarms","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinderfarms \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kinderfarm.."},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cleveland Clinic Research Shows that Melatonin is a Promising Candidate for Prevention and Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Melatonin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland .."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Announces Issuance of Second Patent for the Treatment of Alzheimer\u2019s Using THC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"IGC Pharma Announces a $3 Million Private Placement of its Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"O-Bank Co., Ltd.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ O-Bank Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer\u2019s Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."}]

    Find Clinical Drug Pipeline Developments & Deals for PREVENTION 4 (MELATONIN)

    Menu

    PREVENTION 4 (MELATONIN)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IGC Pharma

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            IGC Pharma

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Bradbury Asset Management

                            Deal Size : $3.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

                            Details : The net proceeds will be used for the advancement of company's investigational medicines including IGC-AD1, a natural THC-based oral formulation, as a treatment for agitation in dementia from Alzheimer’...

                            Brand Name : IGC-AD1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 26, 2024

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Bradbury Asset Management

                            Deal Size : $3.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IGC Pharma

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            IGC Pharma

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial

                            Details : IGC-AD1, a combination medicine with a CB1 receptor partial agonist with anti-neuroinflammatory properties. It is under phase 2 clinical development for the treatment of dementia due to Alzheimer’s.

                            Brand Name : IGC-AD1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 17, 2024

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IGC Pharma

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            IGC Pharma

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : O-Bank Co., Ltd.

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Res...

                            Details : The funding will support IGC’s working capital needs primarily related to its Alzheimer’s research, with IGC-AD1, a low-dose tetrahydrocannabinol based formulation, currently in Phase 2 of clinical tr...

                            Brand Name : IGC-AD1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 07, 2023

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : O-Bank Co., Ltd.

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            IGC Pharma

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            IGC Pharma

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Bradbury Asset Management

                            Deal Size : $3.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            IGC Pharma Announces a $3 Million Private Placement of its Common Stock

                            Details : The funds will support the advancement of the Company’s Phase-2 clinical trial of IGC-AD1 (tetrahydrocannabinol), the Company’s promising investigational drug candidate designed to address agitation i...

                            Brand Name : IGC-AD1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 06, 2023

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Bradbury Asset Management

                            Deal Size : $3.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            IGC Pharma

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            IGC Pharma

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC

                            Details : This is a phase I Multiple Ascending Dose (MAD) study to evaluate safety and tolerability of IGC-AD1 (tetrahydrocannabinol) in subjects with AD. Twelve subjects will be enrolled. Three different ascending...

                            Brand Name : IGC-AD1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 21, 2022

                            Lead Product(s) : Tetrahydrocannabinol,Melatonin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cleveland Clinic

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            Cleveland Clinic

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cleveland Clinic Research Shows that Melatonin is a Promising Candidate for Prevention and Treatme...

                            Details : Results from a new Cleveland Clinic-led study suggest that melatonin, a hormone that regulates the sleep-wake cycle and is commonly used as an over-the-counter sleep aid, may be a viable treatment option ...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 13, 2020

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kinderfarms

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            Kinderfarms

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin,Apigenin

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kinderfarms Announces the Launch of Kinderlyte® Sleep and Immunity

                            Details : Kinderlyte's Herbal Sleep Supplement is a doctor-formulated, drug-free sleep aid that uses a proprietary blend of melatonin and calming botanicals such as chamomile, passionflower, and lemon balm to suppo...

                            Brand Name : Kinderlyte Sleep

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 30, 2020

                            Lead Product(s) : Melatonin,Apigenin

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cleveland Clinic

                            Country arrow
                            BioProcess International
                            Not Confirmed

                            Cleveland Clinic

                            Country arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin,Mercaptopurine,Sirolimus

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Melatonin? Stem Cells? Researchers Step Up With Unconventional Approaches To COVID-19

                            Details : Cleveland Clinic compared COVID-19 with the coronavirus that caused the SARS outbreak of 2003 using a technique called “network proximity analysis” to identify combinations of existing drugs.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 16, 2020

                            Lead Product(s) : Melatonin,Mercaptopurine,Sirolimus

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth